Table of Contents
Hepatitis Research and Treatment
Volume 2012, Article ID 864315, 6 pages
http://dx.doi.org/10.1155/2012/864315
Clinical Study

Association of Interferon-Alpha and Ribavirin-Induced Thyroid Dysfunction with Severity of Disease and Response to Treatment in Pakistani Asian Patients of Chronic Hepatitis C

1Department of Physiology, Army Medical College, National University of Sciences and Technology, Islamabad 44000, Pakistan
2Department of Physiology, Shifa Tameer-e-Millat University, Islamabad 44000, Pakistan

Received 18 May 2012; Revised 11 July 2012; Accepted 19 July 2012

Academic Editor: Alessandro Antonelli

Copyright © 2012 Amina Nadeem and Muhammad Aslam. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. World Health Organization, “Hepatitis C. Fact sheet Number 164,” 2012, http://www.who.int/mediacentre/factsheets/fs164/en.
  2. D. L. Thomas, J. Astemborski, R. M. Rai et al., “The natural history of Hepatitis C virus infection: host, viral, and environmental factors,” Journal of the American Medical Association, vol. 284, no. 4, pp. 450–456, 2000. View at Google Scholar · View at Scopus
  3. Y. Tomer, J. T. Blackard, and N. Akeno, “Interferon alpha treatment and thyroid dysfunction,” Endocrinology and Metabolism Clinics of North America, vol. 36, no. 4, pp. 1051–1066, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Földes, K. Dávid, G. Horváth, H. Osztrogonácz, K. Jankovics, and G. Tolvaj, “Thyroid dysfunctions in patients with viral hepatitis treated with interferon-alpha,” Orvosi Hetilap, vol. 145, no. 23, pp. 1211–1216, 2004. View at Google Scholar · View at Scopus
  5. G. Murdolo, D. Francisci, F. Forini et al., “Expression of endocrine autoantibodies in chronic hepatitis C, before and after interferon-α therapy,” Journal of Endocrinological Investigation, vol. 25, no. 11, pp. 938–946, 2002. View at Google Scholar · View at Scopus
  6. M. F. Prummel and P. Laurberg, “Interferon-α and autoimmune thyroid disease,” Thyroid, vol. 13, no. 6, pp. 547–551, 2003. View at Google Scholar · View at Scopus
  7. G. Tarantino, G. Gagliardi, and P. Conca, “Do thyroid abnormalities detected in patients treated for HCV-related chronic hepatitis persist?” International Journal of Immunopathology and Pharmacology, vol. 21, no. 2, pp. 467–469, 2008. View at Google Scholar · View at Scopus
  8. V. Wong, A. X. L. Fu, J. George, and N. W. Cheung, “Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis,” Clinical Endocrinology, vol. 56, no. 6, pp. 793–798, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. F. Morisco, G. Mazziotti, M. Rotondi et al., “Interferon-related thyroid autoimmunity and long-term clinical outcome of chronic hepatitis C,” Digestive and Liver Disease, vol. 33, no. 3, pp. 247–253, 2001. View at Google Scholar · View at Scopus
  10. E. J. Bini and S. Mehandru, “Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study,” Archives of Internal Medicine, vol. 164, no. 21, pp. 2371–2376, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. F. Doi, S. Kakizaki, H. Takagi et al., “Long-term outcome in interferon-α-induced autoimmune thyroid disorders in chronic hepatitis C,” Liver International, vol. 25, no. 2, pp. 242–246, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Friedrich-Rust, J. Theobald, S. Zeuzem, and J. Bojunga, “Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C,” Journal of Viral Hepatitis, vol. 16, no. 3, pp. 168–177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Gelu-Simeon, A. Burlaud, J. Young, G. Pelletier, and C. Buffet, “Evolution and predictive factors of thyroid disorder due to interferon alpha in the treatment of hepatitis C,” World Journal of Gastroenterology, vol. 15, no. 3, pp. 328–333, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. J. F. Huang, W. L. Chuang, C. Y. Dai et al., “The role of thyroid autoantibodies in the development of thyroid dysfunction in Taiwanese chronic hepatitis C patients with interferon-alpha and ribavirin combination therapy,” Journal of Viral Hepatitis, vol. 13, no. 6, pp. 396–401, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. K. M. Kee, C. M. Lee, J. H. Wang et al., “Thyroid dysfunction in patients with chronic hepatitis C receiving a combined therapy of interferon and ribavirin: incidence, associated factors and prognosis,” Journal of Gastroenterology and Hepatology, vol. 21, no. 1, pp. 319–326, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Masood, R. Ghori, A. Memon et al., “Frequency of thyroid disorders during interferon and ribavirin therapy in chronic hepatitis C infection,” Journal of the College of Physicians and Surgeons Pakistan, vol. 18, no. 6, pp. 347–351, 2008. View at Google Scholar · View at Scopus
  17. X. Moncoucy, F. Leymarie, B. Delemer et al., “Risk factors and long-term course of thyroid dysfunction during antiviral treatments in 221 patients with chronic hepatitis C,” Gastroenterologie Clinique et Biologique, vol. 29, no. 4, pp. 339–345, 2005. View at Google Scholar · View at Scopus
  18. A. Nadeem, M. Aslami, D. A. Khan, T. Hussain, and S. A. Khan, “Effects of combined interferon alpha and ribavirin therapy on thyroid functions in patients with chronic hepatitis C,” Journal of the College of Physicians and Surgeons Pakistan, vol. 19, no. 2, pp. 86–90, 2009. View at Google Scholar · View at Scopus
  19. A. Ziaee, F. Esfehanian, S. M. Alavian, and M. Sarreshtedari, “Thyroid dysfunction in patients with chronic viral hepatitis B and C during alpha interferon therapy,” Hepatitis Monthly, vol. 9, no. 2, pp. 110–113, 2009. View at Google Scholar · View at Scopus
  20. L. Shen, C. Bui, R. Mansberg, D. Nguyen, and S. Alam-Fotias, “Thyroid dysfunction during interferon alpha therapy for chronic hepatitis C,” Clinical Nuclear Medicine, vol. 30, no. 8, pp. 546–547, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. U. Schiemann, R. Walli, F. Schmidt, J. Bogner, and M. Gross, “Thyroid hypoechogenicity in patients with chronic hepatitis receiving interferon-alpha therapy: evaluation by standardized grey scale ultrasonography,” European journal of medical research, vol. 7, no. 6, pp. 271–277, 2002. View at Google Scholar · View at Scopus
  22. H. A. Tran, G. E. Malcolm Reeves, R. Gibson, and J. R. Attia, “Development of thyroid diseases in the treatment of chronic hepatitis C with α-interferon may be a good prognosticator in achieving a sustained virological response: a meta-analysis,” Journal of Gastroenterology and Hepatology, vol. 24, no. 7, pp. 1163–1168, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. H. A. Tran, G. E. M. Reeves, and T. L. Jones, “The natural history of interferon-α2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection,” QJM, vol. 102, no. 2, pp. 117–122, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Ridruejo, A. F. Christensen, and O. G. Mandó, “Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin,” European Journal of Gastroenterology and Hepatology, vol. 18, no. 6, pp. 693–694, 2006. View at Google Scholar · View at Scopus
  25. E. J. Bini and S. Mehandru, “Incidence of thyroid dysfunction during interferon alfa-2b and ribavirin therapy in men with chronic hepatitis C: a prospective cohort study,” Archives of Internal Medicine, vol. 164, no. 21, pp. 2371–2376, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Carella, G. Mazziotti, F. Morisco et al., “The addition of ribavirin to interferon-α therapy in patients with hepatitis C virus-related chronic hepatitis does not modify the thyroid autoantibody pattern but increases the risk of developing hypothyroidism,” European Journal of Endocrinology, vol. 146, no. 6, pp. 743–749, 2002. View at Google Scholar · View at Scopus
  27. R. Paraná, M. Cruz, R. Santos-Jesus, K. Ferreira, L. Codes, and T. Cruz, “Thyroid disease in HCV carriers undergoing antiviral therapy with interferon plus ribavirin,” The Brazilian Journal of Infectious Diseases, vol. 4, no. 6, pp. 284–290, 2000. View at Google Scholar · View at Scopus
  28. O. Dalgard, K. Bjøro, K. Hellum et al., “Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy,” Journal of Internal Medicine, vol. 251, no. 5, pp. 400–406, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Carella, G. Mazziotti, F. Morisco et al., “Long-term outcome of interferon-α-induced thyroid autoimmunity and prognostic influence of thyroid autoantibody pattern at the end of treatment,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 5, pp. 1925–1929, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Rodríguez-Torres, C. F. Ríos-Bedoya, G. Ortiz-Lasanta, A. M. Marxuach-Cuétara, and J. Jiménez-Rivera, “Thyroid dysfunction (TD) among chronic hepatitis C patients with mild and severe hepatic fibrosis,” Annals of Hepatology, vol. 7, no. 1, pp. 72–77, 2008. View at Google Scholar · View at Scopus
  31. Y. Nagane, K. Utsugisawa, H. Kizawa, R. Kondoh, and Y. Terayama, “Hypothyroid myopathy caused by interferon-α therapy for chronic hepatitis C,” Clinical Neurology, vol. 45, no. 6, pp. 441–444, 2005. View at Google Scholar · View at Scopus
  32. A. Antonelli, C. Ferri, P. Fallahi et al., “Thyroid disorders in chronic hepatitis C virus infection,” Thyroid, vol. 16, no. 6, pp. 563–572, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Antonelli, C. Ferri, S. M. Ferrari, M. Colaci, D. Sansonno, and P. Fallahi, “Endocrine manifestations of hepatitis C virus infection,” Nature Clinical Practice Endocrinology and Metabolism, vol. 5, no. 1, pp. 26–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Akeno, E. P. Smith, M. Stefan et al., “IFN-α mediates the development of autoimmunity both by direct tissue toxicity and through immune cell recruitment mechanisms,” Journal of Immunology, vol. 186, no. 8, pp. 4693–4706, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Antonelli, S. M. Ferrari, P. Fallahi et al., “Interferon-alpha, -beta and -gamma induce CXCL9 and CXCL10 secretion by human thyrocytes: modulation by peroxisome proliferator-activated receptor-gamma agonists,” Cytokine, vol. 50, no. 3, pp. 260–267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Antonelli, C. Ferri, and P. Fallahi, “Hepatitis C: thyroid dysfunction in patients with hepatitis C on IFN-α therapy,” Nature Reviews Gastroenterology and Hepatology, vol. 6, no. 11, pp. 633–635, 2009. View at Publisher · View at Google Scholar · View at Scopus